Zhican Wang

SD-Acc: Accelerating Stable Diffusion through Phase-Aware Sampling and Hardware Co-Optimizations

Zhican Wang, Guanghui He, Hongxiang Fan

The emergence of diffusion models has significantly advanced generative AI, improving the quality, realism, and creativity of image and video generation. Among them, Stable Diffusion (StableDiff) stands out as a key model for text-to-image generation and a foundation for next-generation multi-modal algorithms. …

cn, gb (code pays fourni par la source)

Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers

Kyle J. Seamon, Yongxian Zhuang, Yu Chi Yang, Sujata Chakraborty et autres

Covalent KRAS G12C inhibitors have changed the treatment landscape for NSCLC and CRC patients, but numerous RAS-mutant cancers lack approved targeted therapies. Here we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tri-complex inhibitor that induced tumor regressions in selected KRAS G13C-mutant xenograft …

us (code pays fourni par la source)

Efficient 3D Gaussian Splatting with Axis-Shared Rasterization and Order-independent Transmittance

Zhican Wang, Guanghui He, Lingjun Gao, Dantong Liu et autres

3D Gaussian Splatting (3DGS) has emerged as a powerful technique for novel view synthesis, combining high-quality reconstruction with efficient rendering. It has been widely adopted in domains such as AR/VR, robotics, and autonomous driving. However, achieving real-time performance on resource-constrained platforms remains …

cn, gb, us (code pays fourni par la source)

Figure 6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) doublet maximizes pathway suppression and favorably modulates the TME of the ICB-refractory 3LL-ΔNRAS model. A, PD of elironrasib, daraxonrasib, and the RAS(ON) doublet in subcutaneous tumors shown as the relative change in pERK expression in tumor cells. Tumor-bearing mice were treated …

Figure 5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Elironrasib and daraxonrasib drive immune-dependent CRs, favorably modulate the TME, and synergize with anti–PD-1 in the immunogenic KPAR1.3 model. A, Tumor growth of subcutaneous tumors treated for 32 days (dashed line indicated treatment stop) with vehicle, elironrasib at 100 mg/kg, daraxonrasib at …

Supplementary Methods 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Detailed PK-TE-PD modeling method

Data from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Abstract To address RAS pathway hyperactivation and targeted therapy resistance in KRASG12C-mutant non–small cell lung cancer (NSCLC), we evaluated the potential of the RAS(ON) G12C-selective covalent inhibitor elironrasib and the RAS(ON) multi-selective inhibitor daraxonrasib combination to maximize RAS pathway suppression and forestall …

Table S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Primary antibody list for IHC staining

Figure 3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) inhibitor doublet drives sustained RAS signaling suppression, inhibits cell proliferation, and induces apoptosis in vivo. A, Target engagement of KRASG12C protein by elironrasib in NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft tumors, shown as the percentage of cross-linked KRASG12C by elironrasib relative to …

Figure 2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) inhibitor doublet forestalls resistance driven by elevated RAS pathway flux. A, Antitumor activity of elironrasib and daraxonrasib as single agents or in combination in the NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft model (n = 8–15 per group). Tumor-bearing mice were treated with …

Table S1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

KM in xenograft models

Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Supplementary Figure 1. The RAS(ON) inhibitor doublet induces deep and durable responses in KRASG12C-mutant NSCLC models and is tolerated based on animal body weight assessment. Supplementary Figure 2. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vitro. Supplementary Figure 3. The RAS(ON) …